Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004042 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00004042: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00004042 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004042, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody F19 in treating patients who have advanced or metastatic cancer.
Interventions
- RADIATION iodine I 131 monoclonal antibody F19
- BIOLOGICAL monoclonal antibody F19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1998-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004042
The ClinicalTrials.gov registry entry for NCT00004042 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which iodine I 131 monoclonal antibody F19 is the first listed.
NCT00004042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004042 about?
NCT00004042 is a clinical study titled "Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody F19 in treating patients who have advanced or metastatic cancer.
What is the current status of trial NCT00004042?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 1998-11. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00004042?
The interventions under investigation include: iodine I 131 monoclonal antibody F19 (RADIATION), monoclonal antibody F19 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004042?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.